A2M has international capabilities to manage and perform complex multinational projects all over the world.
Market access and Reimbursement
Health economics models: cost-effectiveness and budget impact.
Quality of Life and Outcomes Research
A2M is founding partner of Minerva Health Economic Network with more than 200 staff members in the key pharmaceutical markets in Europe, US, Canada, Australia and Japan.
A2M has established successful strategic collaborations in many other countries, including Australia, Canada, Japan, Central and Eastern Europe and former Soviet Union.
A2M staff has successfully interacted with key stakeholders (payers and health authorities) in many markets (e.g., FDA, CVZ, NICE, TLV), establishing relationships that are valuable in being able to provide insightful guidance.
Glocal approach: A2M uses a unique “glocal” approach optimizing global economies of scale with country-specific fine-tuning to local market access authorities.
Long-time experience in global project management provides: 1) consistency in health economic approach across the study countries, and 2) efficiency by obtaining economies of scale (shorter timelines and lower budgets). Examples are multicountry health economic models for Zemplar in chronic kidney disease (8 countries), Synagis in RSV (6 countries) and Versatis in post-herpetic neuralgia (12 countries). (button here to “countries” of “disease” or naar PDF).
The reimbursement dossiers and models by A2M successfully contributed to positive reimbursement decisions by health authorities in many countries.
International expertise across wide range of disease areas and health economic modelling technologies for 20+years in more than 25 countries.
Knowledge of the global payer and regulator landscape and by developing, capturing and communicating the clinical and economic evidence that our clients require to successfully market their products.